# US 10,946,065 B2 · Methods of treating fungal infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,946,065 B2 - Document ID: US10946065B2 - Status: Granted - Kind: B2 - Application number: 16/717,726 - Filed: 2019-12-17 - Published: 2020-04-09 - Granted: 2021-03-16 - Earliest claimed: 2017-03-02 - Assignees: The United States of America as represented by the Secretary of the Navy - Applicants: United States of America as represented by the Secretary of the Navy - Inventors: Nancy Millenbaugh; Jeremy Wesley Gleaton; Dickson Kiprono Kirui - Web page: https://patentgrep.com/patent/US10946065B2 ## CPC - A61K 38/1767: {from invertebrates} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61L 15/44: Medicaments - A61L 15/46: Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61L 2300/25: Peptides having up to 20 amino acids in a defined sequence - A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines - A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to methods of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more antifungal peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7. Antifungal pharmaceutical compositions and dosage forms, including field-deployable dosage forms, comprising one or more of these antifungal peptides are also contemplated herein. ## Claims ### Claim 1 A method of treating a polymicrobial infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7; wherein said BmKn2 and said Kn2-7 peptides comprise a combination of D form and L form amino acids. ### Claim 2 (depends on 1) The method of claim 1, wherein the polymicrobial infection is resistant to one or more conventional anti-microbial drugs. ### Claim 3 (depends on 2) The method of claim 2, wherein said one or more conventional anti-microbial drugs is one or more conventional antifungal agents. ### Claim 4 (depends on 1) The method of claim 1, wherein the polymicrobial infection comprises infection with one or more pathogenic fungi and one or more additional microbes. ### Claim 5 (depends on 4) The method of claim 4, wherein said one or more pathogenic fungi are resistant to one or more conventional anti-fungal agents. ### Claim 6 (depends on 4) The method of claim 4, wherein said one or more pathogenic fungi are selected from the group consisting of Aspergillus; Blastomyces; Candida; Fusarium; Trichosporon; Penicillium; Coccidioides; Cryptococcus neoformans; Cryptococcus gattii; Histoplasma; Mucorales; Pneumocystis; Sporothrix; Trichophyton, Microsporum, Epidermophyton, Exserohilum, and Cladosporium. ### Claim 7 (depends on 6) The method of claim 6, wherein said one or more pathogenic fungi is Candida. ### Claim 8 (depends on 7) The method of claim 7, wherein the pathogenic fungi is Candida albicans. ### Claim 9 (depends on 4) The method of claim 4, wherein the one or more additional microbes comprise bacteria and/or viruses. ### Claim 10 (depends on 4) The method of claim 4, wherein the infection with one or more pathogenic fungi is a planktonic or a biofilm fungal infection, or a combination thereof. ### Claim 11 (depends on 10) The method of claim 10, wherein the biofilm fungal infection comprises a pre-formed biofilm. ### Claim 12 (depends on 1) The method of claim 1, wherein the polymicrobial infection is a wound infection. ### Claim 13 (depends on 1) The method of claim 1, wherein the peptide is dKn2-7. ### Claim 14 (depends on 1) The method of claim 1, wherein the pharmaceutical composition is administered alone, or in combination with a therapeutically effective amount of one or more additional pharmaceutically acceptable agents. ### Claim 15 (depends on 14) The method of claim 14, wherein the one or more additional pharmaceutically acceptable agents is selected from the group consisting of an antimicrobial agent, an analgesic, an anesthetic, an anti-inflammatory agent, a hemostatic agent, an immunomodulator, a wound healing agent, a biofilm dispersal agent, and a biofilm inhibitor agent. ### Claim 16 (depends on 15) The method of claim 15, wherein the wound healing agent is selected from the group consisting of pharmaceutical formulations comprising chitosan, antiseptics, antioxidants, vitamins, minerals, debriding agents, irrigants, hydrocolloids, alginates, hydrofibers, sodium chloride gels, hydroactive pastes, zinc, silver, cell proliferating agents, collagen, biological dressings, skin equivalents, keratinocytes, fibroblasts, platelet-rich plasma, honey, curcumin, papain and bromelain. ### Claim 17 (depends on 15) The method of claim 15, wherein the antimicrobial agent is selected from the group consisting of an antifungal agent, an antibacterial agent, and an antiviral agent.